<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01199042</url>
  </required_header>
  <id_info>
    <org_study_id>ST-1001-ASVWO-MS</org_study_id>
    <nct_id>NCT01199042</nct_id>
  </id_info>
  <brief_title>Bipap Automatic Servo Ventilation (autoSV) Advanced in Central Apnea Patients</brief_title>
  <official_title>BiPAP (Automatic Servo Ventilation) autoSV Advanced in Central Apnea Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philips Respironics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philips Respironics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study testing the Bipap autoSV Advanced Algorithm during full night, in-lab
      polysomnography (PSG) and 3 months at home on patients with Central Sleep Apnea, Hunter
      Cheyne Stokes Respiration, or Complex Sleep Apnea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who qualify will be scheduled for one full night, attended diagnostic PSG, one
      full night attended continuous positive airway pressure (CPAP) titration, and one full night
      attended BiPAP autoSV Advanced titration PSG. Participants will be provided a BiPAP autoSV
      Advanced to use at home for 90 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea/Hypopnea Index (AHI)</measure>
    <time_frame>During a single night of polysomnography lasting up to 8 hours.</time_frame>
    <description>To compare the AHI between the diagnostic CPAP titration and BiPAP autoSV Advanced PSG nights.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>3 months</time_frame>
    <description>To determine if there are changes in subjective sleepiness on the Epworth Sleepiness Scale (ESS) between Baseline (Visit 1) and 3 months (Visit 6). The ESS is an 8 question survey that determines sleepiness, each question is rated as a 0-3 will the total score ranging from 0-24.
Interpretation:
Score 0-7: Unlikely that there is abnormal sleep Score 8-9: Average amount of daytime sleepiness Score 10-15: Possible excessive sleepiness depending on the situation. Patient may want to consider seeking medical attention.
Score 16-24: Excessive sleepiness and patient should consider seeking medical attention
A decrease in the score indicates improvements in a patients overall sleepiness. An increase in the score indicates increased sleepiness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breathing Event Indexes</measure>
    <time_frame>from the first 7 days of BiPAP autoSV Advanced at home treatment to the last 7 days of at home treatment</time_frame>
    <description>To determine if there are changes in breathing event indexes (Encore Pro Software) from the first 7 days of BiPAP autoSV Advanced at home treatment to the last 7 days of at home treatment to assess therapy efficacy.
Values were determined by taking the average of the first 7 days of treatment and comparing them to the average of the last 7 days of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Therapy Pressure Values</measure>
    <time_frame>3 months</time_frame>
    <description>To compare BiPAP autoSV Advanced therapy pressure values (Encore Pro Software) from the first 7 days of BiPAP autoSV Advanced at home treatment to the last 7 days of at home treatment to determine if pressure requirements change over time.
This analysis compares the average pressure support of the first week compared to the average pressure support to the final week.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Cheyne-Stokes Respiration</condition>
  <condition>Sleep Apnea, Central</condition>
  <arm_group>
    <arm_group_label>BiPAP autoSV Advanced Device</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Positive airway pressure device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BiPAP autoSV Advanced</intervention_name>
    <description>The sleep apnea device will be set-up in automatic mode with the settings wide open for the entire night.</description>
    <arm_group_label>BiPAP autoSV Advanced Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females, ages 21-75.

          2. Able and willing to provide written informed consent.

          3. Diagnosis of Central Sleep Apnea such as Hunter Cheyne Stokes Breathing, Complex Sleep
             Apnea, or Central Apnea with current daily Opioid use or any other predominant central
             sleep apnea.

               1. For participants diagnosed with Hunter Cheyne Stokes Breathing, at least 3 cycles
                  of crescendo-decrescendo breathing amplitude AND either a Central Apnea Index
                  (CAI) ≥ 5/hour OR the crescendo-decrescendo cycles last at least 10 consecutive
                  minutes from an attended Diagnostic Polysomnogram (PSG).

               2. For participants diagnosed with Central Sleep Apnea with current daily Opioid use
                  or any other predominant central sleep apnea, an Apnea/Hypopnea Index (AHI) ≥ 15
                  and CAI &gt; 5 from an attended Diagnostic PSG.

               3. For participants diagnosed with Complex Sleep Apnea, an AHI ≥ 15 and CAI &gt; 5 from
                  a CPAP titration.

          4. Systolic blood pressure &gt; 80 mm Hg at Visit 1.

          5. Agreement to undergo a full-night, attended Diagnostic PSG.

          6. Agreement to undergo a full-night, attended CPAP titration PSG.

          7. Agreement to undergo a full-night, attended BiPAP automatic Servo Ventilation (autoSV)
             Advanced titration PSG

        Exclusion Criteria:

          1. Active participation in another interventional research study.

          2. Diagnosis of acute decompensated heart failure.

          3. Surgery of the upper airway, nose, sinus or middle ear within the last 90 days.

          4. Major medical or psychiatric condition that would interfere with the demands of the
             study or the ability to complete the study. For example, severe unstable chronic lung
             disease, neuromuscular disease, cancer, or end stage renal failure.

          5. Qualifying for or awaiting heart transplantation.

          6. Currently prescribed oxygen therapy (e.g. as needed, nocturnal, or continuous).

          7. At home treatment with adapted Servo Ventilation (ASV) or Bilevel Positive Airway
             Pressure (PAP) therapies.

          8. Unable to use PAP therapies due to physical (e.g. facial structural abnormalities) or
             cognitive (e.g. dementia) issues.

          9. Participants in whom PAP therapy is medically contraindicated.

         10. Uncontrolled hypertension (systolic ≥ 200 mm Hg/diastolic ≥ 120 mm Hg).

         11. Narcolepsy.

         12. Untreated Restless Legs Syndrome.

         13. Periodic Limb Movement arousal index &gt; 20/hr.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahrokh Javaheri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sleepcare Diagnostics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gaylord Hospital - Gaylord Sleep Research</name>
      <address>
        <city>Wallingford</city>
        <state>Connecticut</state>
        <zip>06492</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Research Group</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleepcare Diagnostics</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <results_first_submitted>August 5, 2015</results_first_submitted>
  <results_first_submitted_qc>March 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2016</results_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Cheyne-Stokes Respiration</mesh_term>
    <mesh_term>Sleep Apnea, Central</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twenty-nine patients were enrolled between September 2010 and February 2013. Two participants did not meet) criteria after centralized scoring of diagnostic and CPAP polysomnograms (PSGs) and were excluded from analysis. Twenty-seven participants (five women) completed 3 nights in-laboratory attended PSG, and 26 completed 3 months of follow-up.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Diagnostic, Continuous Positive Airway Pressure (CPAP), ASV</title>
          <description>All participants first underwent a full night, attended diagnostic PSG. Eligible participants then had an attended full night Continuous Positive Airway Pressure (CPAP) manual titration followed by full night, attended, but automated titration with the BiPAP automatic Servo Ventilation.(AutoSV) Advanced™ (Philips Respironics, Murrysville, PA), device.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Sleep Laboratory (3 Nights)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Didn't meet inclusion/exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>At Home (3 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diagnostic, Then CPAP, Then BiPAP autoSV Advanced</title>
          <description>Diagnostic, then CPAP, then BiPAP autoSV Advanced (within-subjects design)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American, Irish, Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Apnea/Hypopnea Index (AHI)</title>
        <description>To compare the AHI between the diagnostic CPAP titration and BiPAP autoSV Advanced PSG nights.</description>
        <time_frame>During a single night of polysomnography lasting up to 8 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Apnea-Hypopnea Index</title>
            <description>Participants had Diagnostic PSG where the Apnea-Hypopnea Index was measured</description>
          </group>
          <group group_id="O2">
            <title>Continuous Positive Airway Pressure Apnea-Hypopnea Index</title>
            <description>The CPAP machine was used to determine the Apnea-Hypopnea Index.</description>
          </group>
          <group group_id="O3">
            <title>BiPAP autoSV Apnea-Hypopnea Index</title>
            <description>The BiPAP autoSV machine was used to determine the Apnea-Hypopnea Index</description>
          </group>
        </group_list>
        <measure>
          <title>Apnea/Hypopnea Index (AHI)</title>
          <description>To compare the AHI between the diagnostic CPAP titration and BiPAP autoSV Advanced PSG nights.</description>
          <units>Apnea-Hypopnea events per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" spread="24"/>
                    <measurement group_id="O2" value="37" spread="22"/>
                    <measurement group_id="O3" value="12" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epworth Sleepiness Scale</title>
        <description>To determine if there are changes in subjective sleepiness on the Epworth Sleepiness Scale (ESS) between Baseline (Visit 1) and 3 months (Visit 6). The ESS is an 8 question survey that determines sleepiness, each question is rated as a 0-3 will the total score ranging from 0-24.
Interpretation:
Score 0-7: Unlikely that there is abnormal sleep Score 8-9: Average amount of daytime sleepiness Score 10-15: Possible excessive sleepiness depending on the situation. Patient may want to consider seeking medical attention.
Score 16-24: Excessive sleepiness and patient should consider seeking medical attention
A decrease in the score indicates improvements in a patients overall sleepiness. An increase in the score indicates increased sleepiness.</description>
        <time_frame>3 months</time_frame>
        <population>26 participants completed the 3-month home follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>BiPAP autoSV Advanced Device</title>
            <description>Over the 90-day home treatment period, the Auto-Servo Ventilation (ASV) device consistently treated obstructive and central Sleep Disordered Breathing (SDB) events.</description>
          </group>
        </group_list>
        <measure>
          <title>Epworth Sleepiness Scale</title>
          <description>To determine if there are changes in subjective sleepiness on the Epworth Sleepiness Scale (ESS) between Baseline (Visit 1) and 3 months (Visit 6). The ESS is an 8 question survey that determines sleepiness, each question is rated as a 0-3 will the total score ranging from 0-24.
Interpretation:
Score 0-7: Unlikely that there is abnormal sleep Score 8-9: Average amount of daytime sleepiness Score 10-15: Possible excessive sleepiness depending on the situation. Patient may want to consider seeking medical attention.
Score 16-24: Excessive sleepiness and patient should consider seeking medical attention
A decrease in the score indicates improvements in a patients overall sleepiness. An increase in the score indicates increased sleepiness.</description>
          <population>26 participants completed the 3-month home follow-up.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (visit 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (visit 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breathing Event Indexes</title>
        <description>To determine if there are changes in breathing event indexes (Encore Pro Software) from the first 7 days of BiPAP autoSV Advanced at home treatment to the last 7 days of at home treatment to assess therapy efficacy.
Values were determined by taking the average of the first 7 days of treatment and comparing them to the average of the last 7 days of treatment.</description>
        <time_frame>from the first 7 days of BiPAP autoSV Advanced at home treatment to the last 7 days of at home treatment</time_frame>
        <population>26 participants completed the 3-month home follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>BiPAP autoSV Advanced Device</title>
            <description>Positive airway pressure device
BiPAP autoSV Advanced: The sleep apnea device will be set-up in automatic mode with the settings wide open for the entire night.</description>
          </group>
        </group_list>
        <measure>
          <title>Breathing Event Indexes</title>
          <description>To determine if there are changes in breathing event indexes (Encore Pro Software) from the first 7 days of BiPAP autoSV Advanced at home treatment to the last 7 days of at home treatment to assess therapy efficacy.
Values were determined by taking the average of the first 7 days of treatment and comparing them to the average of the last 7 days of treatment.</description>
          <population>26 participants completed the 3-month home follow-up.</population>
          <units>Apnea-Hypopnea events per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Therapy Pressure Values</title>
        <description>To compare BiPAP autoSV Advanced therapy pressure values (Encore Pro Software) from the first 7 days of BiPAP autoSV Advanced at home treatment to the last 7 days of at home treatment to determine if pressure requirements change over time.
This analysis compares the average pressure support of the first week compared to the average pressure support to the final week.</description>
        <time_frame>3 months</time_frame>
        <population>26 participants completed the 3-month home follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic, Continuous Positive Airway Pressure (CPAP), ASV</title>
            <description>All participants first underwent a full night, attended diagnostic PSG. Eligible participants then had an attended full night Continuous Positive Airway Pressure (CPAP) manual titration followed by full night, attended, but automated titration with the BiPAP automatic Servo Ventilation.(AutoSV) Advanced™ (Philips Respironics, Murrysville, PA), device.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Therapy Pressure Values</title>
          <description>To compare BiPAP autoSV Advanced therapy pressure values (Encore Pro Software) from the first 7 days of BiPAP autoSV Advanced at home treatment to the last 7 days of at home treatment to determine if pressure requirements change over time.
This analysis compares the average pressure support of the first week compared to the average pressure support to the final week.</description>
          <population>26 participants completed the 3-month home follow-up.</population>
          <units>cm/H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of study: 2 years and 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diagnostic, Then CPAP, Then BiPAP autoSV Advanced</title>
          <description>Participants had a diagnostic PSG, then CPAP and BiPAP autoSV. Participants then went home and used the autoSV for 90 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Shahrokh Javaheri</name_or_title>
      <organization>Bethesda North Hospital</organization>
      <phone>513-793-7378</phone>
      <email>shahrokhjavaheri@icloud.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

